quinuclidines has been researched along with Emesis in 283 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.35) | 18.7374 |
| 1990's | 3 (1.06) | 18.2507 |
| 2000's | 59 (20.85) | 29.6817 |
| 2010's | 191 (67.49) | 24.3611 |
| 2020's | 29 (10.25) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyoshi, K; Hata, A; Inui, N; Kubota, K; Morise, M; Okada, M; Okamoto, I; Saeki, T; Shinagawa, N; Sugawara, S; Takeda, M; Tamura, T; Watanabe, Y | 1 |
| Abdul Rahman, MHFB; Abdullah, MM; Ahmad Annuar, MA; Ahmad Badruddin, RBA; Chong, KJ; Lai, CNB; Lam, KS; Lau, KL; Low, JSH; Md Yusof, M; Ng, SC; Nonis, JG; Yap, BK | 1 |
| Burke, JE; Hess, RS; Silverstein, DC | 1 |
| Al Bawab, AQ; Al Shawakri, E; Al-Qawasmeh, B; Alhifany, AA; Alkhatib, NS; Halloush, S; Koeller, J | 1 |
| Lai, J; Li, C; Li, P; Li, Y; Li, Z; Rastogi, S | 1 |
| Fukazawa, E; Harada, K; Ichimata, M; Kobayashi, T; Matsuyama, F; Nakano, Y | 1 |
| Bertolini, F; Bonizzoni, E; Bria, E; Carnio, S; Cassano, A; Cavanna, L; Celio, L; Chiari, R; Cogoni, AA; Collovà, E; Cortinovis, D; De Placido, S; Gernone, A; Letizia, A; Martelli, O; Misino, A; Petrelli, F; Pilotto, S; Pisconti, S; Vittimberga, I; Zanelli, F | 2 |
| Aapro, M; Bonizzoni, E; Celio, L; Montani, E | 1 |
| Aapro, M; Eriksson, J; Lezzi, C; Nilsson, J; Piovesana, V; Turini, M | 1 |
| Dalessandro, C; DeRenzo, JS; Herlich, A; Holder-Murray, JM; Ibinson, JW; Kentor, ML; Nettrour, JF; Williams, BA | 1 |
| Abe, M; Aogi, K; Iihara, H | 1 |
| Bailey, WL; Navari, RM; Nelson, WW; Shoaib, S; Singh, R; Zhang, W | 1 |
| Egawa, T; Hayashi, T; Kawada, K; Matsuo, K; Nakano, T; Shimokawa, M; Uchiyama, M | 1 |
| Minotti, G | 1 |
| Aapro, M; Navari, R; Scotté, F; Zelek, L | 1 |
| Hata, A; Inui, N; Kubota, K; Morise, M; Saeki, T; Tamura, T; Toi, Y; Yoneshima, Y | 1 |
| Ariga, H; Ishii, H; Kamada, K; Kobayashi, M; Matsuoka, K; Saito, Y; Sakata, Y; Segawa, M; Sugiura, A; Tsuji, S; Tsuji, Y | 1 |
| Benedetti, F; Bonizzoni, E; Bozzoli, V; Capria, V; Chiusolo, P; Codega, P; Cupelli, L; Cupri, A; De Risi, C; Di Renzo, N; Federico, V; Guarini, A; Mazza, P; Mengarelli, A; Messa, AR; Musso, M; Pastore, D; Perrone, T; Scimè, R; Specchia, G | 1 |
| Bettschart-Wolfensberger, R; Hartnack, S; Kantyka, ME; Kutter, APN; Meira, C | 1 |
| Berends, JC; Berkhof, J; Beusink, M; Brouwer, S; Toffoli, EC; van der Vorst, MJDL; van Linde, ME; van Voorthuizen, T; van Zweeden, AA; Verheul, HMW; Vrijaldenhoven, S | 1 |
| Behbahany, K; Bubalo, J | 1 |
| Anzai, Y; Ishida, Y; Kawahara, F; Kimoto, S; Kouuchi, A; Saito, N; Saito-Inoue, K; Watanabe, T | 1 |
| Bruera, E; Gallagher, C; Hui, D; Javle, M; Kaseb, A; Liu, D; Maddi, R; Overman, M; Puac, V; Shelal, Z; Yennurajalingam, S | 1 |
| Gopinath, B; Jamshed, N; Kappagantu, V; Mathew, R | 1 |
| Fujisaki, H; Goto, H; Hara, J; Ishida, Y; Koga, Y; Koh, K; Kosaka, Y; Kumamoto, T; Matsumoto, K; Mochizuki, S; Suzuki, R; Yuza, Y | 1 |
| Barkate, H; Bhagat, S; Dattatreya, PS; Patil, S; Vaswani, B | 1 |
| Bachet, JB; Bourgeois, H; Brocard, F; Chauffert, B; Debourdeau, P; Lefeuvre-Plesse, C; Leheurteur, M; Mayeur, D; Scotté, F; Simon, H; Wagner, JP; Zelek, L | 1 |
| Shirley, M | 1 |
| Canale, FA; Console, G; Cusumano, G; Di Costanzo, A; Ferreri, A; Gallo, S; Gangemi, T; Irrera, G; Loddo, V; Loteta, B; Martino, M; Meliambro, N; Moscato, T; Naso, V; Paviglianiti, A; Porcino, D; Porto, G; Provenzano, PF; Pugliese, M; Romeo, V; Rossetti, AM; Russo, L | 1 |
| Chan, SW; Lu, Z; Rudd, JA; Subhan, F; Ullah, I | 1 |
| Dupuis, LL; Flank, J; Freedman, J; Gibson, P; Holdsworth, MT; Madden, JR; Orsey, A; Patel, P; Phillips, R; Portwine, C; Robinson, PD; Sung, L; Thackray, J | 1 |
| Basharova, E; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, A | 1 |
| Doggrell, SA | 1 |
| Isobe, T; Iwamoto, Y; Kaneko, M; Kenmotsu, H; Kikugawa, M; Koizumi, S; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nishiyama, F; Omori, S; Ono, A; Takahashi, T; Wakuda, K; Yokoyama, K | 1 |
| Bonizzoni, E; Celio, L; Croce, D; Di Turi, R; Nardulli, P; Perrone, T; Restelli, U; Saibene, G; Scolari, F | 1 |
| Abe, M; Arai, N; Ariizumi, H; Baba, Y; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Murai, S; Nakamaki, T; Nakashima, H; Saito, B; Tsukamoto, H; Uto, Y; Yanagisawa, K | 1 |
| Adachi, K; Ikejiri, F; Inoue, M; Ito, S; Jo, Y; Kawakami, K; Kumanomido, S; Miyake, T; Okada, T; Okada, Y; Onishi, C; Suzuki, R; Suzumiya, J; Takahashi, F; Takahashi, T | 1 |
| An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z | 1 |
| Akashi, K; Kadoyama, K; Kamezaki, K; Kato, K; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Takenaka, K; Uchida, M | 1 |
| Gourd, E | 1 |
| Deng, X; Kong, XR; Li, CC; Liang, X; Peng, L; Tan, J; Wang, S; Yang, C; Zhang, J; Zhao, Z | 1 |
| Ishiguro, T; Ogishima, D; Ota, T; Sugimori, Y; Ujihira, T | 1 |
| Arai, T; Hashimoto, H; Iwasa, S; Minato, K; Nagashima, K; Nakao, M; Nakayama, T; Ohyanagi, F; Sakai, H; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Terakado, H; Yamamoto, N; Yanai, T | 1 |
| Aapro, M; Chang, J; Chessari, S; Dechaphunkul, A; Feng, J; Jordan, K; Lanzarotti, C; Lu, S; Wang, D; Zhang, L | 1 |
| Hamakawa, H; Ibaragi, S; Kitamura, N; Kodani, I; Mishima, K; Miyamoto, Y; Nakashiro, K; Ryoke, K; Sasaki, A; Sento, S; Takamaru, N; Ueyama, Y; Yamamoto, T | 1 |
| Boccia, R; Calcanes, G; Caruana, D; McBride, A; Mosier, M; Vacirca, J | 1 |
| Barnes, E; Chan, S; Chow, E; Chung, H; DeAngelis, C; Drost, L; Ganesh, V; Pasetka, M; Pulenzas, N; Tsao, M; Wan, BA; Yee, C; Zaki, P; Zhang, L | 1 |
| Chiu, L; Chow, R; DeAngelis, C; Lam, H; Milakovic, M; Popovic, M; Tsao, M | 1 |
| Celio, L; Fabbroni, C | 1 |
| Badalamenti, G; Bazan, V; Casarin, A; De Luca, I; Incorvaia, L; Messina, C; Musso, E; Ricciardi, MR; Russo, A | 1 |
| Cartagena-Albertus, JC; Engel Manchado, J; Moise, A; Montoya Alonso, JA; Moya García, S | 1 |
| Fukui, T; Inui, N; Iwashima, A; Kanehara, M; Kubota, K; Kumagai, T; Minato, K; Morise, M; Saeki, T; Sugawara, S; Takeda, Y; Tamura, T; Yoshimori, K | 1 |
| Fabi, A; Malaguti, P | 1 |
| Kubota, K; Saeki, T; Segawa, Y; Sekine, I | 1 |
| Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E | 1 |
| Grunberg, SM; Rugo, HS; Slusher, B | 1 |
| Iwashima, A; Kagamu, H; Kobayashi, O; Makino, M; Miura, S; Miyao, H; Narita, I; Okajima, M; Sato, K; Tanaka, H; Tanaka, J; Watanabe, S; Yokoyama, A; Yoshizawa, H | 1 |
| Navari, R | 1 |
| Hatake, K; Ito, Y; Nakayama, Y; Takahashi, S; Tanabe, M | 1 |
| Agustoni, F; Celio, L; Damian, S; De Benedictis, E; De Braud, F; Mariani, P; Ricchini, F | 1 |
| Berger, MJ; Blazer, MA; Crawford, BS; Flynn, JM; Griffith, NL; Layman, RM; Lustberg, MB; Mrozek, E; Phillips, GS; Ramaswamy, B; Shapiro, CL; Wenzell, CM; Wesolowski, R | 1 |
| Ballinari, G; Borsaru, GP; Choi, BS; Di Renzo, N; Voisin, D | 1 |
| Goto, H; Myojo, T; Osawa, H | 1 |
| Belli, C; Dahl, T; Herrstedt, J; Ruhlmann, CH | 1 |
| Blazer, M; Mori-Vogt, S | 1 |
| Abhyankar, S; Aljitawi, OS; Deauna-Limayo, D; Ganguly, S; McGuirk, JP; Wick, JA | 1 |
| Agustoni, F; Braud, FD; Celio, L; Dotti, K; Niger, M; Ricchini, F | 1 |
| Ballinari, G; Barbour, SY; Cox, D; Morrow, GR; Schwartzberg, L; Thorn, MD | 1 |
| Hashimoto, H; Murakami, M; Senba, S; Siraishi, T; Yamaguchi, I; Yamaguchi, K | 1 |
| Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP | 1 |
| Billio, A; Clarke, MJ; Morello, E | 2 |
| Johnson, RA | 1 |
| Iwase, O; Nakajima, A; Nakamura, H; Okuyama, K; Takayanagi, R; Yamada, Y; Yokoyama, H; Yoshimoto, K | 1 |
| Alkam, T; Chebolu, S; Darmani, NA; Vaezi, M; Zhong, W | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M | 1 |
| Affronti, ML; Friedman, HS; Herndon, JE; Schlundt, S; Schneider, SM | 1 |
| Algarra, SM; Azanza, JR; Blanco Prieto, M; Campanero, MA; del Barrio, A; Gomez-Guiu, A; Guillén Grimá, F; Gurpide, A; Lopez-Picazo, JM; Perez-Gracia, JL; Sadaba, B | 1 |
| Blouin, GC; Reddy, P; Yeh, YC | 1 |
| Chan, KK; Chow, E; Deangelis, C; Lam, H; Poon, M; Popovic, M; Pulenzas, N; Tsao, M; Warr, DG; Yip, C; Zhang, L | 1 |
| Goto, T; Hara, S; Ikari, Y; Ishitsuka, K; Katsuya, H; Masaki, M; Nakashima, Y; Ogata, K; Sato, E; Takamatsu, Y; Tamura, K; Tanaka, T | 1 |
| Aapro, M; Bondarenko, I; Borroni, ME; Cardona-Huerta, S; Grunberg, S; Karthaus, M; Lorusso, V; Oprean, C; Rizzi, G; Rossi, G; Rugo, H; Sarosiek, T; Schwartzberg, L | 1 |
| Chang, KH; Chen, YK; Chou, CW; Hwang, WL; Teng, CL; Yu, YB | 1 |
| Alyasova, A; Bondarenko, I; Gralla, RJ; Hesketh, PJ; Lisyanskaya, A; Palmas, M; Rizzi, G; Rossi, G | 1 |
| Balser, C; Borroni, ME; Bosnjak, SM; Gralla, RJ; Hontsa, A; Jordan, K; Rizzi, G; Rossi, G | 1 |
| Cooke, K; Isaza, N; Koh, RB; Robertson, SA; Xie, H | 1 |
| Arai, Y; Habuchi, T; Hamada, S; Hinotsu, S; Kamba, T; Kawai, K; Kawakami, K; Narita, S; Nishiyama, H; Ogawa, O; Yamada, S | 1 |
| Hay Kraus, BL | 3 |
| Abe, M; Furuya, K; Hasegawa, K; Hirashima, Y; Itamochi, H; Ito, K; Kai, K; Kuritani, K; Matoda, M; Nasu, K; Otsuki, T; Sato, S; Takano, M; Takeshima, N; Terao, K; Tsubamoto, H | 1 |
| Errico, A | 1 |
| Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y | 1 |
| Andrews, PLR | 1 |
| Bonizzoni, E; Celio, L; Di Nicola, M; Gianni, AM; Magni, M; Mirabile, A | 1 |
| Fukahori, S; Fukuda, Y; Kitazaki, T; Kohno, S; Nakamura, Y; Oyanagi, K; Soda, H | 1 |
| Hanawa, S; Mitsuhashi, A; Nishikimi, K; Shozu, M; Tate, S; Uno, T; Usui, H; Watanabe-Nemoto, M; Yamamoto, N | 1 |
| Boccia, R; Cooper, W; Gabrail, N; Gralla, RJ; O'Boyle, E; Raftopoulos, H | 1 |
| Brygger, L; Herrstedt, J | 1 |
| Navari, RM | 7 |
| Bolotin, D; Brock, WT; Moses, K; Patricelli, K; Quimby, JM | 1 |
| Aapro, M; Karthaus, M; Lorusso, V | 1 |
| Thompson, CA | 1 |
| Wang, SY; Yang, ZJ; Zhang, L | 1 |
| Aoki, Y; Hayashi, K; Higuchi, T; Igarashi, K; Inatani, H; Kato, T; Kimura, H; Nishida, H; Shimozaki, S; Shirai, T; Takeuchi, A; Tanzawa, Y; Tsuchiya, H; Yamamoto, N | 1 |
| Chebolu, S; Darmani, NA; Mercadante, F; Zhong, W | 1 |
| Bianchi, S; Cappelli, S; De Luca Cardillo, C; Detti, B; Fambrini, M; Francolini, G; Furfaro, IF; Livi, L; Mangoni, M; Meacci, F; Meattini, I; Muntoni, C; Nori, J; Orzalesi, L; Scoccianti, S; Scotti, V | 1 |
| Borroni, ME; Filippov, A; Grunberg, SM; Karthaus, M; Lorusso, V; Rizzi, G; Rossi, G; Singh-Arora, R; Tibor, C | 1 |
| Angelelli, L; Ballatori, E; Caserta, C; Cavanna, L; Ciuffreda, L; Colantonio, I; Fasola, G; Fatigoni, S; Fava, S; Ionta, MT; Licitra, L; Massidda, B; Mirabile, A; Palladino, MA; Roila, F; Ruggeri, B; Tocci, A; Zerilli, F | 1 |
| Aapro, M; Jahn, F; Jordan, K | 1 |
| Doi, A; Hirayama, M; Kitayama, H; Kondo, T; Sugiyama, J; Tsuji, Y | 1 |
| Aapro, MS; Rugo, HS; Schwartzberg, LS | 1 |
| Abramovitz, RB; Gaertner, KM | 1 |
| Furukawa, N; Ito, F; Kanayama, S; Tanase, Y | 1 |
| Calcagnile, S; Cox, D; Kashef, K; Lanzarotti, C; Natale, JJ; Rossi, G; Spinelli, T | 1 |
| Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F | 1 |
| Himelfarb, MA; Litterio, NJ; Lorenzutti, AM; Martín-Flores, M; Zarazaga, MP | 1 |
| Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A | 1 |
| Fujiwara, S; Kanemura, M; Ohmichi, M; Sasaki, H; Terai, Y; Tsunetoh, S | 1 |
| Hayakawa, O; Iwasaki, M; Matsuura, M; Mizunuma, M; Nishikawa, A; Saito, T; Satohisa, S; Tanaka, R; Tanaka, S; Teramoto, M | 1 |
| Baek, JH; Choi, YJ; Chung, JS; Joo, YD; Kim, HJ; Kim, YS; Koh, SJ; Lee, EM; Lee, HG; Lee, WS; Oh, SY; Seol, YM; Yun, EY | 1 |
| Boccia, R; Cooper, W; Gralla, RJ; O'Boyle, E; Raftopoulos, H | 1 |
| Enomoto, T; Katoh, H; Kikuchi, M; Kosaka, Y; Kuranami, M; Minatani, N; Nishimiya, H; Sato, T; Sengoku, N; Tanino, H; Waraya, M; Watanabe, M | 1 |
| Aapro, M; Bosnjak, S; Hesketh, PJ; Jordan, K; Rugo, H; Schwartzberg, L | 1 |
| Rojas, C; Slusher, BS | 1 |
| Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K | 1 |
| Boesch, JM; Campoy, L; Gleed, RD; Kirch, PJ; Learn, MM; Martin-Flores, M; Mastrocco, A; Sakai, DM | 1 |
| Kabanov, SN; Kalabanova, EA; Mitashok, IS; Storozhakova, AE; Svetitskaya, YV; Vladimirova, LY | 1 |
| Keating, GM | 1 |
| Enomoto, N; Fujisawa, T; Hayakawa, H; Imokawa, S; Inui, N; Karayama, M; Koshimizu, N; Kuroishi, S; Kusagaya, H; Matsuda, H; Nakamura, Y; Shirai, T; Suda, T; Toyoshima, M; Yamada, T; Yokomura, K | 1 |
| Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE | 1 |
| Aapro, MS; Roeland, E; Schwartzberg, LS | 1 |
| Ahn, HY; Bashaw, D; Griebel, D; He, R; Kim, I; Lee, SC; Mehrotra, N; Mulberg, A; Sinha, V; Sohrabi, F; Wang, J | 1 |
| Boccia, R; Cooper, W; O'Boyle, E | 1 |
| Christensen, TB; Dohn, LH; Feyer, P; Halekoh, U; Hansen, O; Herrstedt, J; Hilpert, F; Keefe, D; Kristensen, G; Paludan, M; Ruhlmann, CH; Rønnengart, E | 1 |
| Aapro, M; Gralla, RJ; Hesketh, PJ; Jordan, K; Palmas, M; Rizzi, G; Rossi, G | 1 |
| Hou, F; Le, Q; Li, H; Li, W; Liu, S; Shi, Q; Zheng, L; Zong, S | 1 |
| Asano, C; Haegawa, I; Horio, Y; Kadowaki, S; Kajita, M; Komori, A; Maeda, A; Mizutani, A; Muro, K; Narita, Y; Nomura, M; Oze, I; Taniguchi, H; Ura, T; Yoshida, T | 1 |
| Hashizume, J; Higuchi, N; Kitahara, T; Kodama, Y; Matsunaga, N; Nakamura, T; Sakamoto, T; Sasaki, H; Sato, K; Yamaguchi, K | 1 |
| Liaw, CC; Wu, CE; Yang, CK | 1 |
| Aogi, K; Inoue, K; Kitagawa, C; Kubota, K; Ogura, T; Saito, M; Sakai, H; Sekine, I; Yanagita, Y; Yoshizawa, H | 1 |
| Boesch, JM; Campoy, L; Gleed, RD; Learn, MM; Martin-Flores, M; Mastrocco, A; Sakai, DM | 1 |
| Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S; Wada, T; Yano, T | 1 |
| Du, Q; Xu, XL; Yu, B; Zhai, Q; Zhu, B | 1 |
| Hanawa, S; Matsuoka, A; Mitsuhashi, A; Nishikimi, K; Shozu, M; Tate, S; Uno, T; Usui, H | 1 |
| Herrstedt, J; Ruhlmann, CH | 1 |
| Arata, K; Azuma, K; Fujiwara, K; Goto, K; Hashimoto, H; Hayashi, T; Kogure, Y; Matsui, R; Nagase, S; Nakao, M; Nogami, N; Ohyanagi, F; Seki, N; Shimada, T; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Yamamoto, N; Yamanaka, T | 1 |
| Fujita, A; Hatsuyama, T; Kobayashi, M; Sato, H; Sekine, K; Umehara, K; Wakamoto, A | 1 |
| Alice K, P; Badyal, D; Kwatra, G; Mukhopadhyay, S | 1 |
| Gomyo, H; Goto, H; Imamura, Y; Inui, Y; Ito, M; Kakiuchi, S; Kawamoto, S; Kitagawa, K; Kurata, K; Matsuoka, H; Minami, H; Minami, Y; Miyata, Y; Mizuno, I; Mizutani, Y; Murayama, T; Nomura, T; Sanada, Y; Sugimoto, T; Tominaga, R; Yakushijin, K; Yamamoto, K | 1 |
| Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T | 1 |
| Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M | 1 |
| Fang, W; Hong, S; Huang, Y; Kang, S; Luo, Y; Sheng, J; Yang, Y; Zhan, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, N | 1 |
| Aapro, M; Bondarenko, I; Borroni, ME; Cardona-Huerta, S; Hansen, V; Karthaus, M; Oprean, C; Rizzi, G; Rossi, G; Rugo, H; Sarosiek, T; Schwartzberg, L | 1 |
| Aapro, M; Alyasova, AV; Bošnjak, SM; Gralla, RJ; Hesketh, PJ; Jordan, K; Lisyanskaya, AS; Palmas, M; Rizzi, G; Rossi, G | 1 |
| Himelfarb, MA; Invaldi, SH; Litterio, NJ; Lorenzutti, AM; Martín-Flores, M; Zarazaga, MP | 1 |
| Chen, H; Chen, LH; Chen, Z; Meng, ZQ; Ning, ZY; Xie, J; Zhang, CY; Zhu, XY | 1 |
| Furukawa, N; Ito, F | 1 |
| Keser, GO; Yalcin, E | 1 |
| Aapro, M; Rizzi, G; Rossi, G; Rugo, HS | 1 |
| Betanzos-Cabrera, Y; Del Angel, VW; Díaz, FC; Lastiri, GG; López-Aguilar, E; Rivera-Márquez, H; Sepúlveda-Vildósola, AC; Villasis-Keever, MA | 1 |
| Ellebaek, E; Herrstedt, J | 1 |
| Astara, G; Dessì, M; Lepori, S; Loi, C; Madeddu, C; Mantovani, G; Massa, E | 1 |
| Devlin, PM; Khan, AJ; Siddiqi, NH | 1 |
| Huang, Y; Liang, H; Liu, D; Liu, W; Si, X; Wang, L; Yu, Z; Zhang, H | 1 |
| Bianchini, C; Bonanno, V; Crescimanno, A; Musso, M; Perrone, T; Polizzi, V; Porretto, F; Scalone, R | 2 |
| Boucher, JF; Clemence, RG; Conder, GA; Sedlacek, HS | 1 |
| Boucher, JF; Clemence, RG; Conder, GA; Eagleson, JS; Ramsey, DS; Sedlacek, HS | 1 |
| Boucher, JF; Clemence, RG; Conder, GA; Eagleson, JS; Kincaid, K; Ramsey, DS; Watkins, JA | 1 |
| Burdette-Radoux, S; Dugan, M; Grunberg, SM; Muss, H; Siebel, M; Weisberg, T; Wood, M | 1 |
| Aogi, K; Inoue, K; Kitagawa, C; Mitsuhashi, S; Ogura, T; Saito, M; Sakai, H; Sekine, I; Yanagita, Y; Yoshizawa, H | 1 |
| Di Maio, M; Perrone, F | 1 |
| De Jonghe, BC; Horn, CC | 1 |
| Giampaglia, M; Lorusso, V; Perrone, T; Petrucelli, L; Saracino, V; Spedicato, A | 1 |
| Hida, T; Imamura, F; Katakami, N; Kubota, K; Maemondo, M; Masuda, N; Segawa, Y; Sekine, I; Shibuya, M; Takeo, S | 1 |
| Aogi, K; Atagi, S; Inoue, K; Isobe, H; Ogura, T; Sano, M; Segawa, Y; Sekine, I; Tokuda, Y; Tsuboi, M | 1 |
| Scott, LJ; Yang, LP | 1 |
| Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P | 1 |
| Chen, Q; Huang, C; Huang, J; Lin, T; Pan, L; Shen, H; Tian, W; Wang, J; Wang, Z; Zhang, L; Zhang, S; Zhou, J | 1 |
| Aapro, M; Bachmann, C; Fabi, A; Medici, M; Nolè, F; Roila, F; Roncoroni, S; Steger, G | 1 |
| Herrstedt, J; Ruhlmann, C | 1 |
| D'Amico, MR; De Simone, G; Loffredo, G; Migliorati, R; Parasole, R; Petruzziello, F; Poggi, V; Ripaldi, M; Zanotta, G | 1 |
| Trepanier, L | 1 |
| Saito, M; Tsukuda, M | 1 |
| Shukla, A | 1 |
| Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC | 1 |
| Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A | 1 |
| Botrel, TE; Clark, L; Clark, OA; Faleiros, E; Paladini, L; Pegoretti, B | 1 |
| Altavilla, A; Cimadon, B; Cortesi, E; D'Antoni, I; De Luca, C; De Sanctis, R; Del Signore, E; Di Seri, M; Gamucci, T; Gori, B; Grande, R; Lapadula, V; Longo, F; Mansueto, G; Quadrini, S; Stumbo, L | 1 |
| Ardizzoia, A; Bajetta, E; Bertolini, A; Bichisao, E; Buonadonna, A; Capobianco, AM; Cavanna, L; Celio, L; Denaro, A; Fabi, A; Frustaci, S; Isa, L; Piazza, E | 1 |
| Cao, R; Dong, X; Huang, J; Liu, L | 1 |
| Goyal, A; Gupta, YK; Padhy, BM; Shanmugam, SP | 1 |
| Buda, G; Cantaffa, R; De Paolis, MR; Di Renzo, N; Dondi, A; Federico, M; Liardo, E; Mancuso, S; Mannina, D; Montanini, A; Muci, S; Olivieri, A; Patti, C; Plati, C; Stelitano, C | 1 |
| Ajioka, H; Akizawa, Y; Kitamura, R; Morita, F; Takimoto, H; Yoshida, K | 1 |
| Alt, J; Cantoreggi, S; Li, Y; Pietra, C; Rojas, C; Sebastiani, S; Slusher, BS; Stathis, M; Thomas, AG; Zhang, J | 1 |
| Beveridge, R; Bubalo, JS; DeGroot, TJ; Giralt, SA; Hurd, DD; Mangan, KF; Maziarz, RT; Mendoza, FL; Rubenstein, EB; Schuster, MW | 1 |
| Atri, R; Bhutani, G; Dhankar, R; Gupta, MC; Kaushal, J; Kaushal, V; Verma, S | 1 |
| Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L | 1 |
| Likun, Z; Tao, ZL; Xiang, J; Xin, D; Yi, B | 1 |
| Buchner, D; Cox, D; Hatoum, HT; Lin, SJ | 1 |
| Balu, S; Buchner, D; Craver, C; Gayle, J | 2 |
| Balu, S; Cox, D; Craver, C; Gayle, J; Morrow, G; Schwartzberg, L | 1 |
| Balu, S; Buchner, D; Jackson, J; Jain, G; Schwartzberg, L | 1 |
| Alterini, R; Bosi, A; Carrai, V; Caruso, JP; Landi, C; Perrone, T; Puccini, B; Rigacci, L | 1 |
| Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G | 1 |
| Demirag, MK; Demircan, S; Erdem, D; Gonullu, G; Yucel, I | 1 |
| Aogi, K; Inoue, K; Katakami, N; Kuranami, M; Masuda, N; Mizutani, M; Sakai, H; Yanagita, Y; Yoshizawa, H | 1 |
| Alibhai, HI; Lee, K; Mathis, A | 1 |
| Basch, E; Chesney, M; Clark-Snow, RA; Feyer, PC; Flaherty, AM; Freundlich, B; Hesketh, PJ; Kris, MG; Lyman, GH; Morrow, G; Prestrud, AA; Rao, KV; Schwartz, RN; Somerfield, MR | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Hiura, K; Komori, H; Sato, H; Suzuki, C; Yamamoto, M | 1 |
| Hesketh, PJ; Sanz-Altamira, P | 1 |
| Gao, HF; Liang, Y; Wu, HY; Zhang, DS; Zhou, NN | 1 |
| Araz, M; Ata, OY; Dogan, U; Yavas, C; Yavas, G | 1 |
| Abernethy, AP; Rangwala, F; Zafar, SY | 1 |
| Mamoudou, AD; Nadaraja, S; Rosthoej, S; Schroeder, H; Thomassen, H; Wehner, PS | 1 |
| Bassett, R; Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, K; Mahoney, S; Noor, R; Papadopoulos, N | 1 |
| Azevedo, W; Jacobs, P; Matsouka, P; Pinto, A; Schwartzberg, LS | 1 |
| Chen, J; Gu, D; Jin, Y; Sun, W; Xu, Z; Yang, J | 1 |
| Giampaglia, M; Gnoni, A; Lorusso, V; Perrone, T; Petrucelli, L; Saracino, V | 1 |
| Ata, OY; Dogan, U; Ozdemir, K; Tekinalp, M; Yavas, C; Yavas, G | 1 |
| Ahmed, R; Cox, D; Hesketh, PJ; Komorowski, AW; Morrow, G | 1 |
| Li, RC; Qiu, H; Zheng, LJ | 1 |
| Balu, S; Buchner, D; Cox, D; Hatoum, HT; Lin, SJ | 1 |
| Aapro, MS; Bajetta, E; Bonizzoni, E; Celio, L; Perrone, T; Sebastiani, S | 1 |
| Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M | 1 |
| Nakayama, Y; Shinohara, Y; Takahashi, K; Torigoe, T; Yamaguchi, K | 1 |
| Cho, I; Kim, KI; Lee, DE; Lee, HS; Oh, JM; Yoon, JH; Yoon, SS | 1 |
| Gray, SE; Nagy, CK; Navari, RM | 1 |
| Boccia, R; Franco-Gonzales, E; Grunberg, S; Rubenstein, E; Voisin, D | 1 |
| Aapro, M; Gralla, R; Labianca, R; Lichinitser, M; Macciocchi, A; Mezger, J; Peschel, C; Sleeboom, H; Tonini, G; Van Der Vegt, S | 1 |
| Cartmell, A; Charu, V; Eisenberg, P; Figueroa-Vadillo, J; Grunberg, S; Hajdenberg, J; Macciocchi, A; Zamora, R | 1 |
| Grunberg, SM; Koeller, JM | 1 |
| Cornett, PA; Eisenberg, P; Macciocchi, A; MacKintosh, FR; Ritch, P | 1 |
| Scott, LJ; Siddiqui, MA | 1 |
| Rittenberg, CN | 1 |
| Viale, PH | 1 |
| Ihbe-Heffinger, A; Lordick, F; Peschel, C | 1 |
| Rubenstein, EB | 1 |
| Olver, IN | 1 |
| Schwartzberg, L | 1 |
| Navari, RM; Province, PS | 1 |
| Lipp, HP | 1 |
| Fatigoni, S; Roila, F | 1 |
| Aapro, MS; Bertoli, LF; Grunberg, SM; Lordick, F; Macciocchi, A; Manikhas, GM; Morrica, B; Olivares, G; Suarez, T; Tjulandin, SA; Yunus, F | 1 |
| Santini, D; Tonini, G; Vincenzi, B | 1 |
| Padezanin, S | 1 |
| Awab, A; Chaudhary, L; Hamadani, M; Tfayli, A | 1 |
| Cartmell, A; Charu, V; Ferguson, S; Ginkel, A; Grote, T; Hajdenberg, J | 1 |
| Arevalo-Araujo, R; Grote, T; Hajdenberg, J; Latimer, LA; Yee, L | 1 |
| Clemence, RG; de la Puente-Redondo, VA; Rowan, TG; Tilt, N | 1 |
| McNulty, R | 1 |
| Urba, S | 1 |
| Benchaoui, HA; Clemence, RG; de la Puente-Redondo, VA; Rowan, TG; Siedek, EM; Tilt, N | 2 |
| Herrstedt, J | 1 |
| Chowhan, N; Einhorn, LH; Hanna, NH; Johnson, CS; Loehrer, PJ; McClean, J; Navari, RM; Passik, SD; Vinson, J | 1 |
| Brames, MJ; Bubalo, J; Cullen, MT; Dreicer, R; Einhorn, LH; Nichols, CR | 1 |
| van Noort, R | 1 |
| Wilkes, G | 1 |
| Hamaguchi, T | 1 |
| Herrington, JD; Jaskiewicz, AD; Song, J | 1 |
| Andel, J; Angleitner-Boubenizek, L; Bernhart, M; Busch, K; Gehmacher, O; Hernler, T; Kastner, U; Lanz-Veit, A; Petru, E; Pluschnigg, U; Polachova, J; Rohde, M; Schiller, L; Schramböck, R; Stangl, W; Steger, G; Thödtmann, R; Zabernigg, A | 1 |
| Bunger, A; Cox, SR; Hickman, MA; Lin, J; Mahabir, S; McCall, RB; Miskell, C | 1 |
| Clark, R; Eglen, RM; Hegde, SS; Johnson, LG; Lee, CH; Smith, WL; Whiting, RL | 1 |
| Berger, J; Bonhaus, DW; Clark, RD; Eglen, RM; Kowalczyk, BA; Lee, CH; Michel, AD; Miller, AB; Repke, DB; Weinhardt, KK | 1 |
| Schmid, PB | 1 |
60 review(s) available for quinuclidines and Emesis
| Article | Year |
|---|---|
Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective.
Topics: Antiemetics; Antineoplastic Agents; Humans; Nausea; Quinuclidines; Vomiting | 2023 |
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Isoquinolines; Nausea; Pyridines; Quinuclidines; Vomiting | 2021 |
Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Infant; Isoquinolines; Male; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Serotonin Antagonists; Vomiting | 2017 |
Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?
Topics: Administration, Cutaneous; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2017 |
Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Dexamethasone; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Radiotherapy; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2018 |
An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
Topics: Animals; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Isoquinolines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Radiotherapy; Serotonin 5-HT3 Receptor Antagonists; Substance P; Treatment Outcome; Vomiting | 2013 |
Emerging treatments in chemotherapy-induced nausea and vomiting.
Topics: Allosteric Regulation; Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2013 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Humans; Induction Chemotherapy; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2013 |
WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2013 |
Evidence to support use of palonosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drugs, Generic; Evidence-Based Medicine; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2014 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinolines; Long QT Syndrome; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Isoquinolines; Nausea; Palonosetron; Quality of Life; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Emetics; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2014 |
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Isoquinolines; Molecular Structure; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2015 |
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.
Topics: Animals; Antiemetics; Antineoplastic Agents; Drug Combinations; Drug Discovery; Guideline Adherence; Humans; Isoquinolines; Nausea; Neurokinin-1 Receptor Antagonists; Practice Guidelines as Topic; Pyridines; Quinuclidines; Serotonin Antagonists; Spiro Compounds; Treatment Outcome; Vomiting | 2015 |
Netupitant/palonosetron (Akynzeo) for chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Combinations; Humans; Isoquinolines; Nausea; Pyridines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2016 |
Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Guideline Adherence; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2015 |
Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Topics: Antiemetics; Antineoplastic Agents; Drug Combinations; Humans; Isoquinolines; Nausea; Neurokinin-1 Receptor Antagonists; Pyridines; Quinuclidines; Spiro Compounds; Vomiting | 2015 |
Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Drug Combinations; Humans; Isoquinolines; Nausea; Practice Guidelines as Topic; Pyridines; Quinuclidines; Vomiting | 2015 |
Exposure-Response of Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Isoquinolines; Logistic Models; Male; Nausea; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting | 2016 |
New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Vomiting | 2016 |
Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Network Meta-Analysis; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2017 |
Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Middle Aged; Nausea; Pyridines; Quinuclidines; Treatment Outcome; Vomiting; Young Adult | 2017 |
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Humans; Isonipecotic Acids; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2008 |
Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Clinical Trials, Phase III as Topic; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Piperazines; Piperidines; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Palonosetron: in the prevention of nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Drug Interactions; Humans; Isoquinolines; Nausea; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Topics: Animals; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2009 |
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2010 |
Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2010 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indoles; Metoclopramide; Nausea; Ondansetron; Prochlorperazine; Quinolizines; Quinuclidines; Ranitidine; Sucralfate; Vomiting; Weight Loss | 2010 |
Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
Topics: Animals; Antiemetics; Antineoplastic Agents; Dopamine Antagonists; Evidence-Based Medicine; History, 20th Century; History, 21st Century; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2010 |
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Glucocorticoids; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Topics: Antiemetics; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Risk Factors; Safety; Serotonin Receptor Agonists; Vomiting | 2010 |
[Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist].
Topics: Animals; Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Humans; Injections, Intravenous; Isoquinolines; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Rats; Serotonin Antagonists; Vomiting | 2010 |
A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
Topics: Adult; Antiemetics; Antineoplastic Agents; Constipation; Dexamethasone; Headache; Humans; Infusions, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2011 |
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Radiotherapy; Serotonin Antagonists; Surveys and Questionnaires; Vomiting | 2011 |
Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Gastrointestinal Diseases; Granisetron; Humans; Isoquinolines; Nausea; Neoplasms; Palliative Care; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting; Zingiber officinale | 2012 |
The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Half-Life; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Salvage Therapy; Serotonin 5-HT3 Receptor Antagonists; Stem Cell Transplantation; Transplantation Conditioning; Vomiting | 2012 |
Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2013 |
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase I
Topics: Adult; Age Factors; Aged; Anthracyclines; Antiemetics; Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Multicenter Studies as Topic; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2013 |
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2003 |
Palonosetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Injections, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2004 |
The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Isoquinolines; Male; Nausea; Palonosetron; Prognosis; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2004 |
Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Vomiting | 2005 |
[Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Premedication; Quinuclidines; Treatment Outcome; Vomiting | 2005 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Dexamethasone; Female; Half-Life; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Protein Binding; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Neoplasms; Ondansetron; Palonosetron; Patient Satisfaction; Prognosis; Quality of Life; Quinolizines; Quinuclidines; Treatment Outcome; Tropisetron; Vomiting | 2005 |
Chemotherapy-induced nausea and vomiting: state of the art in 2006.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Humans; Isoquinolines; Medical Oncology; Morpholines; Nausea; Neoplasms; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2006 |
Emerging drugs for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Antipsychotic Agents; Aprepitant; Benzodiazepines; Brain; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Tract; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vagus Nerve; Vomiting | 2006 |
New antiemetic drugs.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Medical Oncology; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Vomiting | 2006 |
New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron.
Topics: Animals; Antineoplastic Agents; Drugs, Investigational; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2005 |
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Drug Therapy, Combination; Humans; Isoquinolines; Metoclopramide; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2007 |
Radiation-induced nausea and vomiting.
Topics: Abdominal Neoplasms; Dexamethasone; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Isoquinolines; Nausea; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Radiotherapy; Serotonin Antagonists; Thoracic Neoplasms; Vomiting | 2007 |
[Medical treatment of chemotherapy-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Ghrelin; Glucocorticoids; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Peptide Hormones; Practice Guidelines as Topic; Quinuclidines; Serotonin Antagonists; Vomiting | 2007 |
[Gastrointestinal complication of cancer chemotherapy].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Diarrhea; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Quinuclidines; Risk; Serotonin Antagonists; Stomatitis; Vomiting | 2007 |
130 trial(s) available for quinuclidines and Emesis
| Article | Year |
|---|---|
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Japan; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Pyridines; Quinuclidines; Time Factors; Treatment Outcome; Vomiting | 2022 |
Effectiveness of orally administered maropitant and ondansetron in preventing preoperative emesis and nausea in healthy dogs premedicated with a combination of hydromorphone, acepromazine, and glycopyrrolate.
Topics: Acepromazine; Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Glycopyrrolate; Hydromorphone; Nausea; Ondansetron; Quinuclidines; Vomiting | 2021 |
Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial.
Topics: Antineoplastic Agents; Child; Dexamethasone; Humans; Isoquinolines; Nausea; Osteosarcoma; Palonosetron; Quinuclidines; Vomiting | 2022 |
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
Topics: Antiemetics; Antineoplastic Agents; Benzeneacetamides; Cisplatin; Dexamethasone; Humans; Nausea; Palonosetron; Piperazines; Pyridines; Quinuclidines; Vomiting | 2022 |
Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Isoquinolines; Palonosetron; Quinuclidines; Vomiting | 2022 |
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Anthracyclines; Antiemetics; Antineoplastic Agents; Aprepitant; Cyclophosphamide; Dexamethasone; Drug Combinations; Female; Humans; Isoquinolines; Male; Nausea; Prospective Studies; Quinuclidines; Vomiting | 2023 |
Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Humans; Nausea; Quinuclidines; Risk Factors; Vomiting | 2023 |
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation:
Topics: Dexamethasone; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Nausea; Neoplasm Recurrence, Local; Pyridines; Quinuclidines; Transplantation, Autologous; Vomiting | 2020 |
Prospective, controlled, blinded, randomized crossover trial evaluating the effect of maropitant versus ondansetron on inhibiting tranexamic acid-evoked emesis.
Topics: Animals; Antiemetics; Antifibrinolytic Agents; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Method; Female; Male; Ondansetron; Prospective Studies; Quinuclidines; Tranexamic Acid; Vomiting | 2020 |
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Humans; Male; Metoclopramide; Nausea; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2021 |
[Efficacy of Antiemetic Therapy with Aprepitant, Palonosetron, and Dexamethasone in Patients Receiving Oxaliplatin-Based Chemotherapy].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Humans; Japan; Oxaliplatin; Palonosetron; Quinuclidines; Vomiting | 2020 |
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pilot Projects; Pyridines; Quinuclidines; Vomiting | 2021 |
Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Double-Blind Method; Humans; Infant, Newborn; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2021 |
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Humans; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2021 |
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Topics: Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Aprepitant; Double-Blind Method; Humans; Isoquinolines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Vomiting | 2021 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2017 |
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Olanzapine; Palonosetron; Quinuclidines; Thoracic Neoplasms; Vomiting | 2017 |
A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Isoquinolines; Lymphoma; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Treatment Outcome; Vomiting | 2018 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Thalidomide; Vomiting; Young Adult | 2017 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans; Infant; Infant, Newborn; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Vomiting | 2018 |
A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Outcome Assessment, Health Care; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2017 |
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2018 |
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving h
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Asia; Cisplatin; Dexamethasone; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Pyridines; Quinuclidines; Vomiting | 2018 |
Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Mouth Neoplasms; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2017 |
Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
Topics: Animals; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Diarrhea; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Loperamide; Male; Neoplasms; Paclitaxel; Quinuclidines; Random Allocation; Vomiting | 2019 |
Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Pyridines; Quinuclidines; Treatment Outcome; Vomiting | 2019 |
Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis.
Topics: Age Factors; Antiemetics; Antineoplastic Agents; Female; Humans; Isoquinolines; Male; Middle Aged; Multivariate Analysis; Nausea; Palonosetron; Precision Medicine; Quinuclidines; Risk Factors; Sex Factors; Smoking; Vomiting | 2013 |
The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2013 |
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Dexamethasone; Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2015 |
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Constipation; Dexamethasone; Doxorubicin; Female; Headache; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2013 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Pilot Projects; Prospective Studies; Quinuclidines; Vomiting | 2013 |
Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Nausea; Palonosetron; Prednisolone; Quinuclidines; Vaginal Neoplasms; Vomiting; Vulvar Neoplasms | 2013 |
Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2013 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Gastrointestinal Neoplasms; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Surveys and Questionnaires; Vomiting | 2014 |
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vomiting; Young Adult | 2014 |
Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone.
Topics: Acepromazine; Analgesics, Opioid; Anesthesia, Inhalation; Animals; Antiemetics; Dog Diseases; Dogs; Dopamine Antagonists; Esophagus; Female; Gastroesophageal Reflux; Hydrogen-Ion Concentration; Hydromorphone; Male; Quinuclidines; Vomiting | 2014 |
Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
Topics: Administration, Intravenous; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Subcutaneous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Platinum; Quinuclidines; Treatment Outcome; Vomiting | 2014 |
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Topics: Administration, Oral; Antineoplastic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Effects of maropitant, acepromazine, and electroacupuncture on vomiting associated with administration of morphine in dogs.
Topics: Acepromazine; Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Dopamine Antagonists; Electroacupuncture; Female; Male; Morphine; Quinuclidines; Vomiting | 2014 |
Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Male; Morpholines; Nausea; Neoplasms, Germ Cell and Embryonal; Palonosetron; Quinuclidines; Testicular Neoplasms; Vomiting | 2014 |
Efficacy of orally administered maropitant citrate in preventing vomiting associated with hydromorphone administration in dogs.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Female; Hydromorphone; Male; Quinuclidines; Vomiting | 2014 |
Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Vomiting | 2014 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Electric Stimulation Therapy; Epirubicin; Humans; Ifosfamide; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting; Young Adult | 2014 |
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2014 |
Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Carboplatin; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Japan; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome; Vomiting | 2015 |
The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Treatment Outcome; Uterine Cervical Neoplasms; Vomiting | 2017 |
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, do
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2015 |
Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs.
Topics: Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Drug Administration Schedule; Female; Hydromorphone; Male; Nausea; Quinuclidines; Vomiting | 2014 |
Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial.
Topics: Animals; Cat Diseases; Cats; Double-Blind Method; Kidney Function Tests; Palliative Care; Quinuclidines; Renal Insufficiency, Chronic; Vomiting | 2015 |
Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-da
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Bone Neoplasms; Cross-Over Studies; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting; Young Adult | 2015 |
Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2015 |
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemothe
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Isoquinolines; Italy; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Palonosetron; Quality of Life; Quinuclidines; Risk Factors; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2015 |
Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Patient Preference; Prospective Studies; Quinuclidines; Single-Blind Method; Treatment Outcome; Vomiting | 2015 |
Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Constipation; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Sleep Initiation and Maintenance Disorders; Vomiting | 2015 |
Evaluation of the antiemetic efficacy of maropitant in dogs medicated with morphine and acepromazine.
Topics: Acepromazine; Analgesics, Opioid; Animals; Antiemetics; Dogs; Drug Interactions; Female; Male; Morphine; Prospective Studies; Quinuclidines; Salivation; Single-Blind Method; Vomiting | 2016 |
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Olanzapine; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Cross-Over Studies; Diet; Drug Administration Schedule; Female; Genital Neoplasms, Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial.
Topics: Aged; Antiemetics; Antineoplastic Agents; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Patient Satisfaction; Quinuclidines; Remission Induction; Serotonin Antagonists; Vomiting | 2016 |
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female; Humans; Isoquinolines; Japan; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2016 |
Evaluation of oral maropitant as an antiemetic in cats receiving morphine and dexmedetomidine.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Antiemetics; Cats; Dexmedetomidine; Female; Hysterectomy; Morphine; Ovariectomy; Prospective Studies; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Odds Ratio; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2015 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infant; Internationality; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Isoquinolines; Middle Aged; Nausea; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dexamethasone; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Uterine Cervical Neoplasms; Vomiting | 2016 |
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2016 |
Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
Topics: Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Vomiting | 2016 |
Effects of maropitant in cats receiving dexmedetomidine and morphine.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Antiemetics; Cat Diseases; Cats; Dexmedetomidine; Drug Interactions; Female; Injections, Intramuscular; Injections, Subcutaneous; Morphine; Nausea; Quinuclidines; Single-Blind Method; Visual Analog Scale; Vomiting | 2016 |
Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Cross-Over Studies; Dexamethasone; Esophageal Neoplasms; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Stomach Neoplasms; Vomiting | 2016 |
Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study.
Topics: Adult; Aged; Aprepitant; Chemoradiotherapy; Cisplatin; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Uterine Cervical Neoplasms; Vomiting | 2016 |
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Organoplatinum Compounds; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2017 |
A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Isoquinolines; Japan; Lymphoma; Male; Middle Aged; Nausea; Palonosetron; Prednisolone; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vincristine; Vomiting; Young Adult | 2016 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Transplantation Conditioning; Treatment Outcome; Vomiting; Young Adult | 2017 |
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Topics: Adult; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting; Young Adult | 2017 |
A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs.
Topics: Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Female; Hysterectomy; Male; Metoclopramide; Morphine; Nausea; Orchiectomy; Ovariectomy; Quinuclidines; Vomiting | 2017 |
Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: a single-blind, randomized, controlled trial.
Topics: Acupuncture Points; Adult; Aged; Chemoembolization, Therapeutic; Cisplatin; Combined Modality Therapy; Female; Humans; Isoquinolines; Liver Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Severity of Illness Index; Single-Blind Method; Transcutaneous Electric Nerve Stimulation; Treatment Outcome; Vomiting | 2017 |
Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs.
Topics: Animals; Antiemetics; Dog Diseases; Dogs; Female; Male; Metoclopramide; Ondansetron; Parvoviridae Infections; Parvovirus, Canine; Quinuclidines; Treatment Outcome; Vomiting | 2017 |
Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Female; Humans; Isoquinolines; Male; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2008 |
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: c
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; China; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Hormonal; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Hematologic Neoplasms; Humans; Isoquinolines; Italy; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting; Young Adult | 2009 |
Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Time Factors; Vomiting | 2009 |
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Eating; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Area Under Curve; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Vomiting; Young Adult | 2009 |
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cyclophosphamide; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Vomiting | 2009 |
Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; China; Cross-Over Studies; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Survival Rate; Treatment Outcome; Vomiting; Young Adult | 2011 |
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Child; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Isoquinolines; Maximum Tolerated Dose; Middle Aged; Nausea; Palonosetron; Placebos; Prognosis; Prospective Studies; Quinuclidines; Serotonin Antagonists; Survival Rate; Vomiting; Young Adult | 2010 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioblastoma; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2011 |
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
Topics: Aged; Anthracyclines; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Confidence Intervals; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Health Status Indicators; Humans; Isoquinolines; Male; Middle Aged; Multivariate Analysis; Nausea; Palonosetron; Quinuclidines; Risk Assessment; Serotonin Antagonists; Time Factors; Vomiting | 2011 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2011 |
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano p
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Glucocorticoids; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting; Young Adult | 2011 |
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dexamethasone; Double-Blind Method; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Palonosetron; Quinuclidines; Vomiting | 2011 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Vomiting | 2010 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Isoquinolines; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2010 |
Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Databases, Factual; Female; Follow-Up Studies; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Vomiting | 2011 |
Electrocardiographic findings of palonosetron in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Blood Pressure; Electrocardiography; Female; Heart Rate; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Time Factors; Vomiting; Young Adult | 2012 |
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2012 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Pilot Projects; Quinuclidines; Vomiting | 2012 |
Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Constipation; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Headache; Hiccup; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting; Young Adult | 2013 |
Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Child, Preschool; Denmark; Female; Humans; Isoquinolines; Male; Methotrexate; Nausea; Palonosetron; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinuclidines; Serotonin Antagonists; Time Factors; Vomiting | 2012 |
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Interleukin-2; Isoquinolines; Male; Melanoma; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2012 |
Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2012 |
Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).
Topics: Aged; Antiemetics; Antineoplastic Agents; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Patient Safety; Pilot Projects; Quinuclidines; Salvage Therapy; Treatment Outcome; Vomiting | 2012 |
Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone.
Topics: Analgesics, Opioid; Animals; Antiemetics; Dog Diseases; Dogs; Female; Hydromorphone; Injections, Intramuscular; Male; Preanesthetic Medication; Quinuclidines; Vomiting | 2013 |
[Evaluation of palonosetron for the prevention of nausea and vomiting induced by colon cancer chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2012 |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Humans; Isoquinolines; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2013 |
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2013 |
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2003 |
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinolizines; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2003 |
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2004 |
Palonosetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Injections, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2004 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2006 |
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2006 |
Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Serotonin Antagonists; Severity of Illness Index; Time Factors; Treatment Outcome; Vomiting | 2006 |
Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs.
Topics: Administration, Oral; Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dog Diseases; Dogs; Female; Least-Squares Analysis; Male; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2007 |
The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe.
Topics: Animals; Antiemetics; Dog Diseases; Dogs; Europe; Female; Male; Quinuclidines; Treatment Outcome; Vomiting | 2007 |
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Benzodiazepines; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Olanzapine; Outcome Assessment, Health Care; Palonosetron; Quinuclidines; United States; Vomiting | 2007 |
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Topics: Adult; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoquinolines; Male; Nausea; Neoplasms, Germ Cell and Embryonal; Palonosetron; Quinuclidines; United States; Vomiting | 2007 |
Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs.
Topics: Animals; Antiemetics; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Method; Female; Male; Motion Sickness; Quinuclidines; Treatment Outcome; Vomiting | 2007 |
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Pilot Projects; Quinuclidines; Vomiting | 2008 |
[The psychic effect of ibogaline hydrochloride (alkaloid from Tabernanthe iboga Baill)].
Topics: Adult; Alkaloids; Central Nervous System; Female; Headache; Humans; Hypnotics and Sedatives; Illusions; Intelligence Tests; Male; Methods; Nausea; Placebos; Plants, Medicinal; Psychological Tests; Quinuclidines; Vertigo; Vomiting | 1967 |
94 other study(ies) available for quinuclidines and Emesis
| Article | Year |
|---|---|
Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Benzeneacetamides; Dexamethasone; Hematologic Neoplasms; Humans; Nausea; Palonosetron; Piperazines; Pyridines; Quinuclidines; Vomiting | 2022 |
Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cost-Benefit Analysis; Dexamethasone; Humans; Nausea; Palonosetron; Quinuclidines; Vomiting | 2022 |
Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.
Topics: Animals; Diarrhea; Dog Diseases; Dogs; Doxorubicin; Neoplasms; Neutropenia; Prospective Studies; Quinuclidines; Vomiting | 2022 |
Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cost-Benefit Analysis; Emetics; Humans; Internationality; Nausea; Palonosetron; Quinuclidines; Vomiting | 2022 |
Aim for zero: prevention of postoperative nausea and vomiting using an off-patent five-drug multimodal approach.
Topics: Antiemetics; Dexamethasone; Humans; Postoperative Nausea and Vomiting; Quinuclidines; Vomiting | 2023 |
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Delivery of Health Care; Gastrointestinal Agents; Humans; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2023 |
Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2023 |
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting.
Topics: Antineoplastic Agents; Dexamethasone; Humans; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2023 |
[Multi-Center Joint Study on the Survey of Antiemetic Therapy for the Prevention of Nausea and Vomiting in Combination Therapy with a Mild Emetic Antineoplastic Drug].
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Humans; Nausea; Quinuclidines; Surveys and Questionnaires; Vomiting | 2019 |
Capsule-related dysphagia and the use of netupitant/palonosetron (Akynzeo™) capsules - A report of two cases and a solution.
Topics: Adult; Aged; Antiemetics; Capsules; Deglutition Disorders; Drug Combinations; Female; Humans; Isoquinolines; Male; Nausea; Neurokinin-1 Receptor Antagonists; Pyridines; Quinuclidines; Vomiting | 2021 |
Acute lead poisoning: a diagnostic challenge in the emergency department.
Topics: Abdominal Pain; Acute Disease; Adult; Anemia; Antiemetics; Chelating Agents; Chlordiazepoxide; Cholinergic Antagonists; Constipation; Counterfeit Drugs; Drug Combinations; Emergency Service, Hospital; Humans; Lead Poisoning; Male; Parasympatholytics; Penicillamine; Phenethylamines; Quackery; Quinuclidines; Tomography, X-Ray Computed; Vomiting | 2021 |
The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Combinations; Female; Humans; India; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Pyridines; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2021 |
Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Topics: Antiemetics; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Nausea; Palonosetron; Pyridines; Quality of Life; Quinuclidines; Transplantation, Autologous; Vomiting | 2022 |
Action of Bacopa monnieri to antagonize cisplatin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Antineoplastic Agents; Bacopa; Cisplatin; Isoquinolines; Male; Palonosetron; Plant Extracts; Quinuclidines; Serotonin Antagonists; Shrews; Tiopronin; Vomiting | 2017 |
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.
Topics: Antiemetics; Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Health Resources; Humans; Isoquinolines; Italy; National Health Programs; Nausea; Palonosetron; Pyridines; Quality of Life; Quality-Adjusted Life Years; Quinuclidines; Vomiting | 2017 |
Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Prednisone; Prospective Studies; Quinuclidines; Vincristine; Vomiting; Young Adult | 2018 |
Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
Topics: Adult; Aged; Aging; Antibodies, Monoclonal, Murine-Derived; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cyclophosphamide; Doxorubicin; Female; Granisetron; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Prednisone; Quinuclidines; Risk Factors; Rituximab; Sex Characteristics; Treatment Outcome; Vincristine; Vomiting; Young Adult | 2017 |
Thalidomide reduces chemotherapy-induced vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Epirubicin; Humans; Isoquinolines; Palonosetron; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome; Vomiting | 2017 |
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Dexamethasone; Female; Fluid Therapy; Granisetron; Humans; Injections, Subcutaneous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Treatment Outcome; Vomiting | 2018 |
A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Pilot Projects; Quinuclidines; Radiotherapy; Serotonin Antagonists; Vomiting | 2018 |
Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting.
Topics: Administration, Intravenous; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Radiotherapy; Vomiting | 2018 |
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Pilot Projects; Prospective Studies; Pyridines; Quinuclidines; Receptors, Neurokinin-1; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2019 |
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Isoquinolines; Middle Aged; Nausea; Neoplasm Staging; Palonosetron; Prognosis; Quinuclidines; Serotonin Antagonists; Vomiting | 2013 |
The current status of the use of palonosetron.
Topics: Antineoplastic Agents; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2013 |
[Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a sin
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Combinations; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Risk; Vomiting | 2013 |
Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.
Topics: Adult; Aged; Antiemetics; Aprepitant; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Male; Middle Aged; Morpholines; Multiple Myeloma; Nausea; Palonosetron; Pilot Projects; Quality of Life; Quinuclidines; Transplantation, Autologous; Vomiting | 2014 |
Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Constipation; Creatinine; Granisetron; Humans; Hydroxyindoleacetic Acid; Intestine, Small; Isoquinolines; Models, Biological; Nausea; Oxazines; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
Topics: Animals; Antiemetics; Calcium Channel Blockers; Calcium Channels, L-Type; Drug Synergism; Female; Isoquinolines; Male; Nifedipine; Palonosetron; Pyrroles; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Shrews; Vomiting | 2014 |
Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzimidazoles; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Japan; Male; Middle Aged; Morpholines; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2014 |
Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
Topics: Adult; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Dexamethasone; Female; Glioblastoma; Humans; Isoquinolines; Male; Medication Adherence; Middle Aged; Nausea; Neoplasms; Palonosetron; Quality of Life; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Translational Research, Biomedical; Treatment Outcome; Vomiting | 2014 |
Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2014 |
Palonosetron versus first-generation 5-hydroxytryptamine type 3 receptor antagonists for emesis prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Severity of Illness Index; Transplantation, Homologous; Treatment Outcome; Vomiting; Young Adult | 2014 |
Chemotherapy: NEPA-a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Female; Humans; Isoquinolines; Male; Nausea; Pyridines; Quinuclidines; Vomiting | 2014 |
Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting?
Topics: Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Netupitant-palonosetron combination approved by FDA.
Topics: Antiemetics; Antineoplastic Agents; Drug Approval; Drug Combinations; Drug Interactions; Drug Labeling; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; United States; United States Food and Drug Administration; Vomiting | 2014 |
Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
Topics: Animals; Antiemetics; Cisplatin; Cyclic AMP-Dependent Protein Kinases; Drug Therapy, Combination; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Isoquinolines; Male; Neurokinin-1 Receptor Antagonists; Palonosetron; Protein Kinase C; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Shrews; Vomiting | 2015 |
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Dexamethasone; Half-Life; Humans; Isoquinolines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quality of Life; Quinuclidines; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Drug Combinations; Humans; Isoquinolines; Nausea; Pyridines; Quinuclidines; Vomiting | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting | 2015 |
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Oxonic Acid; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Stomach Neoplasms; Surveys and Questionnaires; Tegafur; Vomiting | 2016 |
[Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Severity of Illness Index; Treatment Outcome; Vomiting | 2015 |
Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Practice Guidelines as Topic; Pyridines; Quality of Life; Quinuclidines; Treatment Outcome; Vomiting | 2015 |
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Topics: Adult; Aged; Antiemetics; Biomarkers, Pharmacological; Dexamethasone; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2016 |
Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bridged Bicyclo Compounds, Heterocyclic; Catheterization, Peripheral; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Liver; Liver Neoplasms; Male; Middle Aged; Morpholines; Nausea; Oxazines; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2016 |
Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Vomiting | 2017 |
[Comparative Study of the Antiemetic Palonosetron for Lung Cancer Patients Treated with a Divided Dose of Cisplatin].
Topics: Antiemetics; Cisplatin; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2016 |
Corrections.
Topics: Arthritis; Capsules; Drug Combinations; Etanercept; Humans; Injections; Isoquinolines; Naltrexone; Nausea; Oxycodone; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Tumor Necrosis Factor-alpha; Vomiting | 2016 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazine; Dexamethasone; Drug Therapy, Combination; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2016 |
Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
Topics: Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Combinations; Female; Humans; Isoquinolines; Male; Nausea; Pyridines; Quinuclidines; Treatment Outcome; Vomiting | 2017 |
Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Morpholines; Nausea; Paclitaxel; Palonosetron; Prospective Studies; Quinuclidines; Vomiting; Young Adult | 2017 |
Palonosetron--a single-dose antiemetic adjunct for hepatic artery radioembolization: a feasibility study.
Topics: Embolization, Therapeutic; Feasibility Studies; Female; Hepatic Artery; Humans; Isoquinolines; Liver Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Treatment Outcome; Vomiting; Yttrium Radioisotopes | 2009 |
Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs.
Topics: Animals; Cross-Over Studies; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Male; Motion Sickness; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2008 |
Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs.
Topics: Animals; Apomorphine; Cross-Over Studies; Dogs; Emetics; Humans; Ipecac; Male; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2008 |
Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
Topics: Administration, Oral; Animals; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Injections, Subcutaneous; Male; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2008 |
Palonosetron: more than just another option?
Topics: Clinical Trials as Topic; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).
Topics: Amygdala; Animals; Antiemetics; Antineoplastic Agents; Area Postrema; Brain; Cisplatin; Disease Models, Animal; Female; Isoquinolines; Mesencephalon; Palonosetron; Proto-Oncogene Proteins c-fos; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Shrews; Solitary Nucleus; Time Factors; Vomiting | 2009 |
Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Transplantation Conditioning; Transplantation, Autologous; Vomiting | 2010 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2009 |
Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety.
Topics: Adolescent; Antiemetics; Bone Marrow Transplantation; Child; Child, Preschool; Female; Humans; Infant; Isoquinolines; Male; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2010 |
Acute pancreatitis attributed to dietary indiscretion in a female mixed breed canine.
Topics: Acute Disease; Animal Feed; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Cell Count; Dehydration; Dog Diseases; Dogs; Female; Medical History Taking; Meloxicam; Pancreatitis; Quinuclidines; Radiography; Tachycardia; Thiazines; Thiazoles; Treatment Outcome; Vomiting | 2010 |
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administration Schedule; Drug Substitution; Emergency Service, Hospital; Fallopian Tube Neoplasms; Female; Health Resources; Humans; Isoquinolines; Length of Stay; Middle Aged; Nausea; Ondansetron; Ovarian Neoplasms; Palonosetron; Patient Readmission; Premedication; Quinuclidines; Risk Assessment; Risk Factors; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting | 2011 |
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Health Status Indicators; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Serotonin Antagonists; Surveys and Questionnaires; Vomiting; Young Adult | 2011 |
Palonosetron induced anaphylaxis in an adult female.
Topics: Adult; Anaphylaxis; Breast Neoplasms; Female; Humans; Isoquinolines; Nausea; Neoplasm Recurrence, Local; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2010 |
The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
Topics: Action Potentials; Animals; Antiemetics; Antineoplastic Agents; Calcium; Cell Line; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Isoquinolines; Male; Neurokinin-1 Receptor Antagonists; Neurons; Nodose Ganglion; Palonosetron; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Substance P; Vomiting | 2010 |
Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cisplatin; Cohort Studies; Cyclophosphamide; Databases, Factual; Female; Follow-Up Studies; Hospitalization; Humans; Isoquinolines; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2012 |
Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Nausea; Outpatients; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; United States; Vomiting; Young Adult | 2011 |
Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Topics: Adolescent; Aged; Antiemetics; Antineoplastic Agents; Databases, Factual; Female; Follow-Up Studies; Humans; Isoquinolines; Male; Middle Aged; Multivariate Analysis; Nausea; Neoplasms; Outpatient Clinics, Hospital; Palonosetron; Quinuclidines; Regression Analysis; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting; Young Adult | 2011 |
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Topics: Adult; Antiemetics; Antineoplastic Agents; Aprepitant; Databases, Factual; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vinblastine; Vomiting; Young Adult | 2012 |
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Vomiting | 2012 |
The use of maropitant to prevent vomiting induced by epidural administration of preservative free morphine through an epidural catheter in a dog.
Topics: Anesthesia, Epidural; Animals; Antiemetics; Dog Diseases; Dogs; Male; Morphine; Narcotics; Quinuclidines; Vomiting | 2011 |
[The efficacy of aprepitant and palonosetron on cisplatin doublet in lung cancer].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2011 |
Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Electrocardiography; Heart Rate; Humans; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting; Young Adult | 2012 |
Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Rate; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Patient Selection; Predictive Value of Tests; Prospective Studies; Quinuclidines; Risk Assessment; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; Time Factors; Turkey; Vomiting | 2012 |
[Comparison of the effect of palonosetron versus tropisetron in prevention of vomiting in patients receiving high dose cisplatin-based chemotherapy].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Eating; Female; Humans; Indoles; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinuclidines; Tropisetron; Vomiting | 2012 |
Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cisplatin; Female; Health Care Surveys; Hospitalization; Humans; Isoquinolines; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2012 |
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Isoquinolines; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Palonosetron; Quinuclidines; Retrospective Studies; Vomiting | 2012 |
Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Topics: Adult; Aged; Alcohol Drinking; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Sex Factors; Treatment Outcome; Vomiting | 2012 |
Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Receptors, Serotonin; Vomiting | 2004 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Tropisetron; Vomiting | 2005 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2005 |
[Second generation of 5-HT3 antagonists].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Male; Neoplasms; Palliative Care; Palonosetron; Quinuclidines; Vomiting | 2005 |
Applying new data to manage CINV: achieving optimal outcomes through a comprehensive care model.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Comprehensive Health Care; Evidence-Based Medicine; Humans; Isoquinolines; Models, Organizational; Morpholines; Nausea; Neoplasms; Nurse's Role; Oncology Nursing; Palonosetron; Patient Care Team; Practice Guidelines as Topic; Quinuclidines; Total Quality Management; Vomiting | 2006 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compounds; Palonosetron; Quinolizines; Quinuclidines; Treatment Outcome; Vomiting | 2006 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Therapeutic Equivalency; Vomiting | 2007 |
Preventing emesis in lung cancer patients.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Lung Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2007 |
[New antiemetics: maropitant citrate].
Topics: Animals; Antiemetics; Quinuclidines; Vomiting | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.
Topics: Adult; Age Factors; Aged; Antiemetics; Antineoplastic Agents; Austria; Breast Neoplasms; Cancer Care Facilities; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Sex Factors; Surveys and Questionnaires; Time Factors; Vomiting | 2008 |
Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats.
Topics: Animals; Cats; Female; Male; Metabolic Clearance Rate; Motion Sickness; Neurokinin-1 Receptor Antagonists; Quinuclidines; Vomiting | 2008 |
Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
Topics: Administration, Oral; Animals; Bradycardia; Dogs; Dose-Response Relationship, Drug; Duodenum; Female; Ferrets; Granisetron; Hemodynamics; Injections, Intravenous; Injections, Subcutaneous; Isoquinolines; Male; Ondansetron; Palonosetron; Quinuclidines; Random Allocation; Rats; Serotonin; Serotonin Antagonists; Stereoisomerism; Vomiting | 1995 |
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.
Topics: Animals; Cisplatin; Computer Simulation; Dogs; Ferrets; Isoquinolines; Male; Models, Molecular; Molecular Structure; Palonosetron; Pyridones; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Antagonists; Stereoisomerism; Structure-Activity Relationship; Vomiting | 1993 |
Palonosetron. RS 25259, RS 25259 197.
Topics: Animals; Antiemetics; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Guinea Pigs; Humans; Isoquinolines; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Rats; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Vomiting | 1999 |